BidaskClub upgraded shares of NantKwest (NASDAQ:NK) from a strong sell rating to a sell rating in a research report sent to investors on Tuesday.
Separately, Zacks Investment Research raised shares of NantKwest from a hold rating to a buy rating and set a $5.00 price objective for the company in a report on Friday, January 12th. Three investment analysts have rated the stock with a sell rating and three have given a hold rating to the company. The stock has an average rating of Hold and a consensus target price of $4.00.
NantKwest stock opened at $4.22 on Tuesday. The company has a quick ratio of 6.35, a current ratio of 6.35 and a debt-to-equity ratio of 0.01. NantKwest has a 12-month low of $2.71 and a 12-month high of $8.45. The company has a market capitalization of $301.11, a P/E ratio of -3.52 and a beta of 2.83.
Institutional investors and hedge funds have recently modified their holdings of the stock. Ardsley Advisory Partners bought a new stake in shares of NantKwest during the fourth quarter worth $112,000. Russell Investments Group Ltd. bought a new stake in shares of NantKwest during the third quarter worth $139,000. SG Americas Securities LLC lifted its position in shares of NantKwest by 254.3% during the third quarter. SG Americas Securities LLC now owns 49,356 shares of the biotechnology company’s stock worth $270,000 after purchasing an additional 35,424 shares during the last quarter. Deutsche Bank AG lifted its position in shares of NantKwest by 116.7% during the fourth quarter. Deutsche Bank AG now owns 67,847 shares of the biotechnology company’s stock worth $304,000 after purchasing an additional 36,542 shares during the last quarter. Finally, Renaissance Technologies LLC lifted its position in shares of NantKwest by 23.2% during the fourth quarter. Renaissance Technologies LLC now owns 232,900 shares of the biotechnology company’s stock worth $1,046,000 after purchasing an additional 43,800 shares during the last quarter. Institutional investors own 15.89% of the company’s stock.
NantKwest Company Profile
NantKwest, Inc is a clinical-stage immunotherapy company. The Company is focused on harnessing the power of the innate immune system by using the natural killer cell to treat cancer, infectious diseases and inflammatory diseases. Its immuno-oncology NK platform has multiple modes to induce cell death against the tumor or infected cell by direct killing by binding to stress ligands expressed by the diseased cell with the release of toxic granules directly into the tumor cell; antibody mediated killing by binding to antibodies administered in combination and enhancing the cancer killing effect of the administered antibody, enabling targeted cell killing through antibody dependent cellular cytotoxicity (ADCC), and target activated killing by binding to known or newly discovered tumor-specific antigens expressed on the surface of tumor cells and inducing cell death by the release of toxic granules directly into the tumor cell and by the release of cytokines and chemokines.
Receive News & Ratings for NantKwest Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NantKwest and related companies with MarketBeat.com's FREE daily email newsletter.